Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

David Errington - Senior Vice President of Investor Relations & Corporate Affairs

Mark Goldsmith - Chairman & Chief Executive Officer

Jack Anders - Senior Vice President of Finance

Conference Call Participants

Marc Frahm - Cowen & Company

Michael Smith - Guggenheim

Christopher Zap - Goldman Sachs

Jonathan Chang - SVB Leerink

Operator

Good day. My name is Katherine, and I'll be your conference facilitator today. Welcome to the Revolution Medicines First Quarter and 2022 Earnings Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions]

I would now like to hand the conference over to David Errington, Revolution Medicines, SVP of Investor Relations and Corporate Affairs for opening remarks. David, you may begin.

David Errington

Thank you, and welcome, everyone, to our first quarter earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer; Dr. Steve Kelsey, the company's President, Research and Development; and Jack Anders, our SVP of Finance and Principal Accounting Officer. Today, we will be referencing selected slides from our corporate presentation. The complete set is available for you to view and download on revmed.com.

As we begin, I would like to note that our presentation will include statements regarding the current beliefs of the company with respect to our business that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are subject to a number of assumptions, risks and uncertainties. Actual results may differ materially from these statements. And except as required by law, the company undertakes no obligation to revise any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or the earnings press release as well as all of the company's filings with the SEC concerning these and other matters.

With that, I will turn the call over to Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer.

Mark Goldsmith

Thanks, David. Good afternoon, everyone. Thank you all for joining us today. I'll start with a few top line comments. We've made great progress in the first quarter. We continue to advance what we believe is the deepest portfolio of RAS targeted therapeutics in the field, led by our RAS on inhibitors in development with significant opportunity for patient impact. excessive RASon-signaling drives some 30% of all human cancers.